Rodman & Renshaw Announces Panel Discussion on Personalized Medicine for Multiple Sclerosis

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), today announced that on April 7, 2010, Rodman will host a panel discussion in its media center with the following panelists:

• Robert B. Darnell, M.D., Ph.D., Investigator, Howard Hughes Medical Institute Heilbrunn Cancer Professor and Senior Physician, The Rockefeller University
• Dawn McGuire, M.D., Chair Clinical Advisory Board, Opexa Therapeutics
• Neil Warma, President and CEO of Opexa Therapeutics

The event will be moderated by Elemer Piros, Ph.D., senior biotechnology analyst at Rodman & Renshaw, LLC. The topic to be covered will be personalized medicine for Multiple Sclerosis.

The presentation will take place at the Rodman & Renshaw Offices (1251 Avenue of the Americas, 20th Floor, New York, NY 10020) at 4:30 PM ET on April 7, 2010. To attend, please RSVP to Marta Wypych at mwypych@rodm.com. Please respond quickly as space is limited. This event also will be webcast live at http://rodm.tv/broadcast.php, Password: mspanel, and it will be broadcast via conference call at the following dial-In Number: (888) 801-6507 or for international callers: (913) 981-5587, Passcode: 7374831. A replay of the discussion will be made available at www.rodm.tv 24 hours after completion of the event.

Background of Scientific Experts:

Robert B. Darnell M.D., Ph.D.

Dr. Robert B. Darnell is an investigator of the Howard Hughes Medical Institute and he is the Heilbrunn Cancer Professor and Senior Physician at the Rockefeller University. Since the identification of autoimmune antigens from his patients, Dr. Darnell and his laboratory have been studying paraneoplastic neurologic disorders (PNDs), an autoimmune disease, for decades. Additionally, Dr. Darnell’s lab has three Investigational New Drug applications approved and is developing cancer vaccines for use in small-scale clinical trials to mimic PND tumor immunity. Dr. Darnell holds four issued patents with six additional patent applications pending. Dr. Darnell has published numerous original papers, as well as invited reviews in top scientific journals, such as Nature, Science, and Neuron. Dr. Darnell’s awards include the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research in 2000, the Derek Denny-Brown Young Neurological Scholar Award in 1998 and the Irma T. Hirschl Trust Career Scientist Award in 1996.

Dr. Darnell has received his undergraduate degree in biology and chemistry from Columbia University in 1979 and earned his M.D. and Ph.D. in 1985 from Washington University School of Medicine in St. Louis, where he specialized in molecular biology. Dr. Darnell trained in internal medicine at Mount Sinai School of Medicine and in neurology at Weill Cornell Medical College, where he was chief neurology resident from 1989 to 1990. In 1990 he began clinical work as a clinical assistant neurologist at Memorial Sloan-Kettering Cancer Center, where he continues to teach as an attending neurologist. He has also remained associate faculty of Weill Cornell in neurology and neuroscience. Dr. Darnell joined Rockefeller University in 1992 as assistant professor and associate physician at The Rockefeller University Hospital. He was named associate professor in 1997 and professor and senior physician in 2000. In 2002 Dr. Darnell was appointed investigator at the Howard Hughes Medical Institute and named Heilbrunn Professor at Rockefeller.

Dawn McGuire M.D.

Dr. Dawn McGuire is the Chair of Opexa’s Clinical Advisory Board and a board certified neurologist with more than a decade of executive leadership in drug development. She currently serves as the chief medical officer of Acologix and prior to that was the chief medical officer of Pepgen Corporation. Dr. McGuire was also formerly chief medical officer of Avigen, Inc. At Elan Pharmaceuticals, she was vice president of clinical research, where she served as development leader for Tysabri, a drug now marketed for the treatment of patients with relapsing forms of multiple sclerosis (MS). From 1999 to 2002, Dr. McGuire served as chief executive officer of Eunoe, Inc. Dr. McGuire also holds several academic and service positions, including American Academy of Neurology committee memberships, peer review committee membership in the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH), and serves on the Advisory Council of the Gill Heart Institute. Dr. McGuire received her B.A. with high honors from Princeton University and her M.D. from Columbia University, College of Physicians & Surgeons. She was trained in Neurology at the University of California, San Francisco, followed by an NIH-funded postdoctoral fellowship in clinical trial design and experimental therapeutics.

About Opexa Therapeutics, Inc.

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Company’s leading therapy, Tovaxin®, is an individualized cellular immunotherapy treatment in Phase IIb clinical development for multiple sclerosis (MS). Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time. Data from the first Phase IIb clinical study showed compelling evidence that Relapsing Remitting MS patients treated with Tovaxin saw overall clinical, MRI, and immunological benefits over the placebo group, including statistical significance for decrease in the Annualized Relapse Rate (ARR), improvement in disability score (EDSS), and improvement in quality of life measures (MSQLI), as well as an excellent safety profile with no serious adverse events related to Tovaxin treatment.

About Rodman & Renshaw

Rodman & Renshaw, LLC is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets and has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005 according to Sagient Research Systems,

MEMBER FINRA SIPC